Hepatologist Dr SK Sarin, speaking at Agenda Aaj Tak, urged people to look for inherited diseases and not wealth to assess a ...

Once considered low risk, this group is now facing a health crisis. The leading researcher studying AAPI cancer rates tells ...

This test evaluates the genetic data in prostate tumor cells obtained from a biopsy ... GPS could quickly become a way to ...

The Leukemia & Lymphoma Society estimates that by year end, 2024 will have seen 187,740 Americans diagnosed with a blood ...

It’s been long known that women with BRCA1 and BRCA2 gene mutations are at higher risk for breast and ovarian cancer. More ...

For years, scientists have looked to a critical piece of immune system machinery - known as the interferon pathway - for answers. There, when our cells sense an infection, they release a protein known ...

Leerink Partnrs lowered their Q1 2025 EPS estimates for Myriad Genetics in a research report issued on Monday, December 9th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Me, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...